A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

Discover a study that demonstrates the effectiveness of guselkumab in treating scalp psoriasis, offering significant symptom ...

Guselkumab improves scalp psoriasis and quality of life in patients with skin of color.

Guselkumab significantly improves psoriasis severity and quality of life compared with placebo in patients with skin of color.

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients with active psoriatic arthritis, according to data presented at the ...

Love Island start Toni Laites is best known for her dramatic entrance into the villa, but behind the glamour she is battling ...

Now, after setting an innovative medicines sales record in the year’s second quarter, it appears J&J’s confidence was well placed.

Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. "Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating ...

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy ...